Shire ViroPharma Incorporated Sustainability Profile
Shire ViroPharma Incorporated, a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has established itself as a leader in developing innovative therapies for rare diseases, particularly in the areas of infectious diseases and gastrointestinal disorders. With a strong focus on research and development, Shire ViroPharma is renowned for its unique product offerings, including treatments that address unmet medical needs. The company has achieved significant milestones, positioning itself as a trusted name in the market. Its commitment to advancing healthcare solutions underscores its reputation for excellence and innovation in the biopharmaceutical sector.
DitchCarbon Score
How does Shire ViroPharma Incorporated's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shire ViroPharma Incorporated's score of 72 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shire ViroPharma Incorporated, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Takeda Pharmaceutical Company Limited, which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its climate strategy, Shire ViroPharma is aligned with the initiatives and targets set by Takeda Pharmaceutical Company Limited. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions across their operations. However, specific reduction targets or achievements for Shire ViroPharma have not been disclosed. The company is also involved in broader climate initiatives, although details on specific pledges or commitments are not available. As a subsidiary, Shire ViroPharma's climate actions are likely influenced by Takeda's overarching sustainability goals, which focus on reducing emissions and enhancing environmental stewardship. In summary, while Shire ViroPharma does not provide specific emissions data or reduction targets, it is part of a corporate family that is actively engaged in climate commitments through Takeda Pharmaceutical Company Limited.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Shire ViroPharma Incorporated's Industry?
How Carbon Intensive is Shire ViroPharma Incorporated's Location?
Shire ViroPharma Incorporated's Scope 3 Categories Breakdown
Shire ViroPharma Incorporated's Scope 3 emissions, which decreased by 23% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 68% of Scope 3 emissions.
Top Scope 3 Categories
Shire ViroPharma Incorporated's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shire ViroPharma Incorporated has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
